Sun Pharma to acquire 100% stake in Antibe Therapeutics

Sun Pharma to acquire 100% stake in Antibe Therapeutics

By: IPP Bureau

Last updated : January 17, 2025 10:44 am



Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation


TARO Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries Limited has entered into an agreement with Antibe Therapeutics, Canada, pursuant to which Sun Pharma has agreed to acquire 100% stake in Antibe Therapeutics Inc.

Antibe Therapeutics is a Canada incorporated corporation based in Ontario, Canada. It is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation. Antibe is currently being managed by a court-appointed receiver, and the receiver is authorized to carry out the sale of Antibe.

The transaction is subject to a Reverse Vesting Order and approval from the Ontario Superior Court of Justice and is expected to be completed before 7th March, 2025.

TARO Pharmaceuticals Sun Pharmaceutical Industries Limited Antibe Therapeutics biotechnology

First Published : January 17, 2025 12:00 am